Nurix Therapeutics (NRIX) Total Current Liabilities (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Total Current Liabilities data on file, last reported at $92.2 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $92.2 million, up 2.46% year-over-year; the trailing twelve-month figure through Feb 2026 was $92.2 million (up 2.46% YoY), and the FY2025 annual result was $86.5 million, down 9.79% from the prior year.
• Total Current Liabilities grew to $92.2 million in Q1 2026 per NRIX's latest filing, from $86.5 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $95.9 million in Q4 2024 and troughed at $61.5 million in Q3 2023.
• A 5-year average of $78.8 million and a median of $80.8 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2025: Total Current Liabilities soared 55.12% in 2022, then declined 9.79% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $70.7 million in 2022, then rose by 23.07% to $87.0 million in 2023, then climbed by 10.23% to $95.9 million in 2024, then decreased by 9.79% to $86.5 million in 2025, then grew by 6.62% to $92.2 million in 2026.
• Business Quant data shows NRIX's Total Current Liabilities at $92.2 million in Q1 2026, $86.5 million in Q4 2025, and $82.4 million in Q3 2025.